The effect of a single i.v. injection of30, 50, and65mg of streptozotocin (Sz) per kg of body weight on blood glucose, plasma insulin and glucagon levels was studied in rats. Responses to glucose of these three parameters were also examined in rats one week after the administration of various doses of Sz alone, Sz with nicotinamide or with picolinamide.
Synopsis The effect of a single i.v. injection of30, 50, and65mg of streptozotocin (Sz) per kg of body weight on blood glucose, plasma insulin and glucagon levels was studied in rats. Responses to glucose of these three parameters were also examined in rats one week after the administration of various doses of Sz alone, Sz with nicotinamide or with picolinamide.
Nicotinamide, 500mg/kg, and picolinamide, 250 mg/kg, were given i.p. 15m in before the injection of 65mg/kg of Sz.
The triphasic pattern was observed after the injection of 65mg/kg of Sz not only in blood glucose and plasma insulin but also in plasma glucagon level fluctuations, the last of which showed a similar pattern to that of blood glucose responses.
Further, the initial hyperglucagonemia had a delay of2hr in onset, when treated with30 and50mg/kg of Sz, respectively. Oral glucose loading resulted in a significant increase of plasma glucagon levels in rats injected with 30 and 50mg/kg of Sz, respectively.
The paradoxical rise of plasma glucagon and glucose intolerance was observed in rats given Sz with nicotinamide, and Sz with picolinamide, as well as in those given Sz alone, 65mg/kg, while there was no significant difference in insulin responses between the pretreated groups of rats and controls.
These results suggest that streptozotocin, even in a nondiabetogenic dose, has effect(s) on the A cell function, and that nicotinamide and picolinamide are active in protecting B cells against the cytotoxic effect, but they do not modify the effect of Sz on the A cell function.
In various species of animals, streptozotocin (Sz) has a diabetogenic action (Rerup, 1970) , which is mediated through the destruction of B cells of pancreatic islets. It has further been shown that nicotinamide protects B cells against the cytotoxic effect (Schein et al., 1967; Schein and Bates, 1968; Dulin and Wyse, 1969; Stauffacher et al., 1970) . Picolinamide was found to prevent a diabetogenic effect of Sz (Doi, 1975 
Results
Acute Response to Sz of Blood Glucose, Plasma Insulin and Glucagon ( Fig.1) The administration of65mg/kg of Sz resulted in the expected triphasic responses of blood glucose (Type P4) levels was observed at the 2nd and 4th hr with a significant decrease of plasma insulin levels. At the7th hr, there was severe hypoglycemia associated with significantly increased plasma insulin levels. Twenty-four and 48hr after treatment, all animals were severely diabetic, characterized by hyperglycemia and a fall in plasma insulin concentrations in the fed states. With inverse proportional changes between blood glucose and plasma insulin responses, unexpected triphasic responses of plasma glucagon concentrations were observed following treatment. Plasma glucagon levels rose markedly2and4hr after treatment and subsequently fell to the initial values at the 7th hr. Twenty-four and48hr after treatment (in fed states), the mean plasma glucagon levels were significantly elevated as compared to those of controls. The pattern was similar to that of blood glucose responses.
In comparison with 65 mg/kg of Sz, 30 mg/kg of Sz resulted in no significant variations of blood glucose levels within7hr after treatment, despite significant decreases of plasma insulin levels. It also resulted in a later appearance of the initial hyperglucagonemia, that is, at the4th hr. Mild but definite hyperglycemia was observed 24and48hr after treatment, associated with less pronounced decreases in plasma insulin concentrations.
At that time, the elevation of plasma gluacgon values was still definite but less pronounced than those of65mg/kg of Sz. Responses of plasma glucagon to50mg/ kg of Sz were nearly the same as those of 30mg/kg of Sz, whereas the ensuing patterns of blood glucose levels were intermediate between those of30and65mg/kg of Sz.
Rats given an injection with buffer alone showed no significant deviations of blood glucose and plasma insulin levels, except for the significant rises of plasma insulin levels in the fed states (at24and 48hr). Small but significant rises of plasma Vol.26 Picolinamide, the isomer of nicotinamide, also prevented the diabetogenic action of Sz, although pretreatment with the isomer induced severer glucose intolerance than nicotinamide-pretreatment. Glucagon responses to glucose in pretreated rats were nearly the same as those of65mg/kg of Sz.
Neither the pretreated rats nor those treated with30mg/kg of Sz showed any signs of overt diabetes, whereas, those given an injection with larger doses of Sz developed overt diabetes.
Discussion
As previously reported (Schein and Bates, 1 968; Stauffacher et al., 1970) and confirmed by the present study, diabetes onset after i.v. injection of Sz, 65mg/kg, is followed by a triphasic pattern with an early Fig.1 , the injection of a diabetogenic dose, 65mg/kg, of Sz was followed by the triphasic pattern in not only blood glucose and plasma insulin but also plasma glucagon level fluctuations, and the pattern of plasma glucagon fluctuations was similar to that of blood glucose responses. These results suggest that the early hyperglycemia is, in part, responsible for the early hyperglucagonemia and hypoinsulinemia.
The observation (Golden et al., 1971 ) that pancreatic islets 1hr after the injection of Sz fail to secrete insulin in response to glucose in vitro supports the hypothesis that the hypoinsulinemia is responsible for a direct inhibitory action of Sz on B cells. The early hyperglucagonemia agrees with the enhanced baseline glucagon secretion following the acute treatment with a diabetogenic dose of Sz (Weir et al., 1976) . The detailed mechanisms of the early hyperglucagonemia are also obscure. The present observations that a nondiabetogenic dose of the agent was also followed by a significant rise of plasma glucagon, which had a delay of 2hr in onset and a similar severity to that observed after a diabetogenic dose, indicate that Sz, even in a nondiabetogenic dose, has a direct effect on the function of not only B cells but also A cells. This hypothesis is supported by the observation (Lazarus and Shapiro, 1972 ) that some necrotic A cells with pyknotic nuclei are observed after Sz.
Oral glucose tolerance tests revealed that a glucose loading was followed by a significant rise of plasma glucagon levels in rats 1week after treatment with Sz, irrespective of the dose, while control rats showed no deviation of plasma glucagon levels. Besides, the paradoxical rise of plasma glucagon was seen not only in rats given a diabetogenic dose of Sz, but also in those given the same dose of Sz with nicotinamide, and Sz with picolinamide, while the insulin response to glucose was not impaired in the pretreated animals. Oral glucose loading caused a decrease in plasma glucagon in normal human subjects (Muller et al., 1970) but not in normal control rats used in this study. The reasons for this are unclear. Coexistence of the capacity of B cells to secrete insulin and the paradoxical glucagon rise found in pretreated rats provides further evidence that Sz has a direct effect on the A cell function and rules out the possibility that the paradoxical rise is a consequence of insulin defficiency.
